RxDoctor Payments Data

Christopher Skalomenos, MD

Internal Medicine · San Antonio, TXNPI 1114416591

Payments from drug & device makers

$927in general payments, 2019–2025

Across 49 payments — averaging $18.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$169
  • Novo Nordisk$142
  • GSK$124
  • Lilly USA, LLC$69
  • Merck$55
  • Medtronic$45
  • plus $323 from 12 others

What the payments were for

  • Food & beverage$927100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$927 in reported general payments places this provider in the 65th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$147,098
Medicare patients
515
Services billed
1,671

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide109$130,008
JardianceEmpagliflozin61$81,234
FarxigaDapagliflozin Propanediol31$46,533
EliquisApixaban37$45,994
RybelsusSemaglutide16$37,780
JanuviaSitagliptin Phosphate30$36,659
TrulicityDulaglutide16$28,836
MounjaroTirzepatide23$24,498
XareltoRivaroxaban16$24,204
EntrestoSacubitril/Valsartan11$8,797
XanaxAlprazolam11$6,080
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$5,587
PremarinEstrogens, Conjugated17$5,352
Atorvastatin Calcium440$3,695
Levothyroxine Sodium309$3,601

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$142$167,789125 claims
Boehringer IngelheimJardiance$14$81,23461 claims
Lilly USA, LLCTrulicity, Mounjaro$69$53,33439 claims
PfizerEliquis, Premarin$43$51,34654 claims
AstraZenecaFarxiga$169$46,53331 claims
MerckJanuvia$55$36,65930 claims
NovartisEntresto$17$8,79711 claims
AbbVieSynthroid$14$3,37848 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →